Neuralink receives Health Canada approval for CAN-PRIME Study
Evidence notes
- Neuralink received Health Canada approval to launch CAN-PRIME, its first international clinical trial.
- CAN-PRIME extends evaluation of the N1 Implant and R1 Robot system outside the United States.
- The trial studies safety and early effectiveness of Neuralink's implant and surgical robot system.
Company context
Neuralink develops implantable brain-computer interfaces and the R1 surgical robot used to place ultra-fine electrode threads.